Sector News

Featured News

June 19, 2022
Sustainability

Borderless is proud to announce that it has recently received a Bronze award from Ecovadis. An initial assessment of the firm’s performance in environmental, labor and human rights matters, placed the firm in the top 50% of companies assessed by Ecovadis.

Latest News

June 3, 2023
Chemical Value Chain

The Chemours Company (NYSE: CC), DuPont de Nemours, Inc. (NYSE: DD) and Corteva, Inc. (NYSE: CTVA) (the “companies”) today announced they have reached an agreement in principle to comprehensively resolve all PFAS-related drinking water claims of a defined class of public water systems that serve the vast majority of the United States population.

June 3, 2023
Sustainability

“One of the worst things that you can do to a garment, in terms of its durability, is wash it.” So says Mark Sumner, a lecturer in sustainable fashion at the University of Leeds. But while he says reducing the frequency of our clothes washing is the right choice for the environment, he doesn’t advocate a complete washing machine moratorium.

June 3, 2023
Diversity & Inclusion

The biggest career wins often come with risk. On our series, The Big Bet, Chief speaks with some of the most powerful members in our network about that single moment when they bet on themselves — and won. When reflecting on her career, Suman Rao, VP Business Technology Group at HelloFresh, says her journey has been “very checkered yet connected.”

June 3, 2023
Borderless Leadership

Large-scale change efforts achieve 24% more of their planned value when a dedicated CTO oversees them, Bain data shows. There are five critical roles a CTO must play, often simultaneously: strategic architect, integrator, operator, coach, and controller. Many CTOs are in the position for the first time and often don’t have a predecessor to lean on, making external coaching or peer mentoring highly valuable.

June 3, 2023
Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

Subscribe to our Weekly Newsletter

Understanding your business is our business

How can we help you?

We're easy to reach